Detalhe da pesquisa
1.
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
N Engl J Med
; 389(17): 1579-1589, 2023 Oct 26.
Artigo
Inglês
| MEDLINE | ID: mdl-37888917
2.
Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials.
Lancet
; 401(10378): 747-761, 2023 03 04.
Artigo
Inglês
| MEDLINE | ID: mdl-36746171
3.
Bimekizumab versus Secukinumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 142-152, 2021 07 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33891380
4.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
N Engl J Med
; 384(12): 1101-1112, 2021 03 25.
Artigo
Inglês
| MEDLINE | ID: mdl-33761207
5.
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Br J Dermatol
; 190(5): 668-679, 2024 Apr 17.
Artigo
Inglês
| MEDLINE | ID: mdl-38226713
6.
JAK inhibition for CD3- CD4+ lymphocytic-variant hypereosinophilic syndrome.
Clin Immunol
; 251: 109275, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-36870379
7.
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
N Engl J Med
; 382(8): 706-716, 2020 02 20.
Artigo
Inglês
| MEDLINE | ID: mdl-32074418
8.
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Br J Dermatol
; 188(2): 198-207, 2023 02 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36763857
9.
Bimekizumab maintenance of response through 3â years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.
Br J Dermatol
; 188(6): 749-759, 2023 05 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36967713
10.
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
J Am Acad Dermatol
; 89(3): 486-495, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37182701
11.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
J Am Acad Dermatol
; 88(1): 40-51, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36115523
12.
Clinical features, therapeutic choice and response by phototype in psoriasis: analysis of the French PsoBioTeq cohort.
Clin Exp Dermatol
; 48(11): 1238-1246, 2023 Oct 25.
Artigo
Inglês
| MEDLINE | ID: mdl-37409606
13.
Quality of life and stigmatization in people with skin diseases in Europe: A large survey from the 'burden of skin diseases' EADV project.
J Eur Acad Dermatol Venereol
; 37 Suppl 7: 6-14, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37806002
14.
Public perception of dermatologists in Europe: Results from a population-based survey.
J Eur Acad Dermatol Venereol
; 37 Suppl 7: 27-37, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37806001
15.
The journey of patients with skin diseases from the first consultation to the diagnosis in a representative sample of the European general population from the EADV burden of skin diseases study.
J Eur Acad Dermatol Venereol
; 37 Suppl 7: 17-24, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37806003
16.
Patient Unique Stigmatization Holistic tool in dermatology (PUSH-D): Development and validation of a dermatology-specific stigmatization assessment tool.
J Eur Acad Dermatol Venereol
; 37(2): 443-450, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36201355
17.
Cav1.4 calcium channels control cytokine production by human peripheral TH17 cells and psoriatic skin-infiltrating T cells.
J Allergy Clin Immunol
; 149(4): 1348-1357, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34653514
18.
Lupus band test can be used in combination with anti-chromatin antibodies and complement analysis to predict transition from cutaneous to systemic lupus.
Clin Immunol
; 234: 108908, 2022 01.
Artigo
Inglês
| MEDLINE | ID: mdl-34896318
19.
The biological basis of disease recurrence in psoriasis: a historical perspective and current models.
Br J Dermatol
; 186(5): 773-781, 2022 05.
Artigo
Inglês
| MEDLINE | ID: mdl-34939663
20.
Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Br J Dermatol
; 187(3): 338-352, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35484697